Tomasz Kula is a co-founder of TScan Therapeutics. During his PhD work at Harvard in the lab of Steve Elledge, he focused on developing new technologies to profile the immune system. In addition to creating the TScan technology, he worked on a high-throughput platform called VirScan to map the targets of anti-viral antibodies. He has been the recipients of multiple fellowships, including the NSF GRFP and the Harvard Biogen Innovation Grant. Tomasz graduated Magna Cum Laude with Highest Honors in Molecular and Cellular Biology from Harvard College.